

*duplicate.*

---

**Ladas & Parry**

Los Angeles Office

5670 Wilshire Boulevard, 21st Floor

Los Angeles, California 90036

**Fax Cover Sheet**

Fax: (323) 934-0202

Phone: (323) 934-2300

---

**To:** Ulrike Winkler  
c/o USPTO

**Facsimile No.** (703) 746-3162

**From:** Tomas Lendvai

**Date:** October 4, 2002

**Pages:** 12 (including this page)

**Subject:** Our Reference: 618769-8 B-4775 PCT

---

**THIS MESSAGE IS INTENDED ONLY FOR USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION WHICH IS PRIVILEGED, CONFIDENTIAL OR OTHERWISE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by fax or telephone and return the original message to us at the above address via mail. We will cheerfully refund your reasonable out-of-pocket expenses. Thank You.**

---

---

**MESSAGE:** Pursuant to our conversation of today, attached please find the relevant copies of PCT Application No. PCT/IT99/00356.

---

EL652176619USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stefano COLLOCA ) Re: Preliminary Amendment  
U.S. Appln. No.: not yet )  
assigned ) Group: not yet assigned  
U.S. Filing Date: concurrently ) Examiner: not yet assigned  
herewith )  
International Application No: )  
PCT/IT99/00356 )  
International Filing Date: )  
8 November 1999 ) Our Ref.: B-4175PCT 618769-8  
For: "CELLS FOR THE PRODUCTION )  
OF HELPER DEPENDENT ADENOVIRAL )  
VECTORS, METHOD FOR THE )  
PREPARATION AND USE THEREOF" ) Date: May 4, 2001

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Attn: United States Designated/Elected Office (DO/EO/US)

Sir:

Prior to examination of the above-identified application, it is respectfully requested that the following amendments be made to the claims:

IN THE CLAIMS

Please replace Claims 7-10, 15-18, 20, 22-24, and 27 with new amended Claims 7-10, 15-18, 20, 22-24, and 27, which are set forth below. (Appendix A, which is enclosed herewith, shows how Claims 7-10, 15-18, 20, 22-24, and 27 were amended to produce new amended Claims 7-10, 15-18, 20, 22-24, and 27.)

7. (Amended) - Cells according to claim 4, wherein said virus is Epstein-Barr virus, the origin of replication is OriP and the activating factor is EBNA-1.